A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
By A. Cortegiani, G. Ingoglia, M. Ippolito, A. Giarratano, S. Einav. Journal of critical care, 2020
988 citations recorded by the source corpus.
Purpose COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19. Methods PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19. Results We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro. Conclusions There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI) framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data from high-quality clinical trials are urgently needed.
Subfields: Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/81d932301e273ac012db2b1a49e63e3a69801685
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Laura Evans
- M. Cecconi
- Mitchell M. Levy
- A. Rhodes
- W. Alhazzani
- M. Møller
- Y. Arabi
- Francesco Di Gennaro
Citations in the corpus
- Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) (2020, background): “A new report in China investigated different dosing regimens of chloroquine and hydroxychloroquine utilizing physiologically-based pharmacokinetic models [25].”
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice (2020, neutral): “Multiple direct acting antivirals are currently under evaluation in randomized control trials to treat COVID-19 including hydroxychloroquine, remdesivir, lopinavir/ritonavir (33) (34) (35) .”
- COVID-19: fear appeal favoring purchase behavior towards personal protective equipment (2020, background): “…few known studies in areas of epidemiological, clinical characteristics, treatment, and clinical outcomes of confirmed cases infected with COVID-19 (Cortegiani et al., 2020; Huang et al., 2020; Li et al., 2020), there are no known studies on the implication for marketing, and the socio-economic…”
- Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review (2020, result): “Other experiments have shown that azithromycin in combination with hydroxychloroquine appeared to have additional benefit, but there are methodologic concerns about the control groups for the study, and the biologic basis for using azithromycin in this setting is unclear [48].”